Infection and Drug Resistance (Apr 2023)
Comparative Efficacy of Super Bioavailable Itraconazole Capsules 50 mg vs 65 mg Twice Daily in the Management of Glabrous Tinea
Abstract
Bela Shah,1 Deval Mistry,2 Dharmender Jairam,1 Kajal Kansara,1 Rutvi Pandya,1 Presha Vasani,1 Dhiraj Dhoot,3 Namrata Mahadkar,3 Sumit Bhushan,3 Hanmant Barkate3 1Department of Dermatology, B J Medical College, Civil Hospital, Ahmedabad, Gujarat, India; 2Mistry Skin Clinic, Ahmedabad, Gujarat, India; 3Department of Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, IndiaCorrespondence: Dhiraj Dhoot, Glenmark Pharmaceuticals Ltd., B D Sawant Marg, Near Bisleri Plant, Chakala, Andheri (E), Mumbai, 400099, India, Tel +919619811219, Email [email protected]: Owing to pharmacokinetic challenges of itraconazole, super-bioavailable itraconazole (SB) was developed and recently approved in strengths of 50mg and 65mg. But comparative study was lacking between these two strengths in glabrous tinea (dermatophytosis) management. Hence, this study was planned to compare the efficacy of both these strengths in dermatophytosis.Methods: One hundred eligible patients were enrolled in this prospective, randomized, clinical study during May-2022 to September-2022 at tertiary hospital in Ahmedabad in adults. Efficacy and safety assessments were done at week-3 and 6 with follow up at week-10 for relapse. Primary objective was to assess the proportion of patients achieving complete cure at week-6 following treatment in both the groups. Secondary outcomes compared safety, clinical and mycological cure rates.Results: Of the 100 patients enrolled, 98 patients (50 in SB-50mg and 48 in SB-65mg group) included in the final analysis. At week 6, 20 patients (40%) and 30 patients (62.5%) achieved complete cure (p < 0.05) in SB-50mg and SB-65mg groups, respectively. In completely cured patients, relapse was reported in 3 (15%) and 5 (17%) patients of SB-50mg and SB-65mg groups, respectively (p = 1). A significant difference was noted in clearance of symptoms and lesions in SB-65mg group (p < 0.05). Moreover, similar results were also obtained in sub-group analysis of recalcitrant dermatophytosis. Both the treatments were found to be safe and well tolerated with no discontinuation.Conclusion: Study result concluded the superiority of SB-65mg over SB-50mg in terms of cure rate and resolution of symptoms in dermatophytosis management.Keywords: comparison, dermatophytosis, efficacy, super-bioavailable itraconazole, 50mg, 65mg
